Novo Nordisk bets $1.1B on Canadian biotech buyout, adding an old approach to obesity pipeline

Novo Nordisk is keeping its foot on the gas as it strives to carve out a strong position in the exploding obesity market, inking a deal worth up to $1.1 billion to buy a Canadian biotech that is dusting off an old approach to triggering weight loss.